OPKO HEALTH, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: February 26, 2026 | OPKO HEALTH, INC. | |
|---|---|---|
| By: | /s/ Phillip Frost, M.D. | |
| Phillip Frost, M.D. | ||
| Chairman of the Board and | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Phillip Frost, M.D. | Chairman of the Board and Chief Executive | February 26, 2026 |
| Phillip Frost, M.D. | Officer(Principal Executive Officer) | |
| /s/ Jane H. Hsiao, Ph.D., MBA | Vice Chairman and Chief Technical Officer | February 26, 2026 |
| Jane H. Hsiao, Ph.D., MBA | ||
| /s/ Elias A. Zerhouni, M.D. | Vice Chairman and President | February 26, 2026 |
| Elias A. Zerhouni, M.D. | ||
| /s/ Steven D. Rubin | Director and Executive Vice President – | February 26, 2026 |
| Steven D. Rubin | Administration | |
| /s/ Adam Logal | Senior Vice President, Chief Financial Officer, | February 26, 2026 |
| Adam Logal | Chief Accounting Officer and Treasurer(Principal Financial Officer) | |
| /s/ Gary J. Nabel, M.D., Ph.D. | Director, Chief Innovation Officer | February 26, 2026 |
| Gary J. Nabel, M.D., Ph.D. | ||
| /s/ Richard Krasno, Ph.D. | Director | February 26, 2026 |
| Richard Krasno, Ph.D. | ||
| /s/ Prem A. Lachman, M.D. | Director | February 26, 2026 |
| Prem A. Lachman, M.D. | ||
| /s/ Roger J. Medel, M.D. | Director | February 26, 2026 |
| Roger J. Medel, M.D. | ||
| /s/ John A. Paganelli | Director | February 26, 2026 |
| John A. Paganelli | ||
| /s/ Richard C. Pfenniger, Jr. | Director | February 26, 2026 |
| Richard C. Pfenniger, Jr. | ||
| /s/ Alice Lin-Tsing Yu, M.D., Ph.D. | Director | February 26, 2026 |
| Alice Lin-Tsing Yu, M.D., Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.